Erik James Hicken

USPTO Granted Patents = 18 (Patent Applications = 1)

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 13.6

ph-index = 3

Forward Citations = 54(Granted Patents)

Location History:

Longmont, CO (US) (2022 - 2023)
Boulder, CO (US) (2013 - 2024)

Company Filing History:

Mirati Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

18 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11932633 - KRas G12C inhibitors (2024-03-19),

2. 11834453 - Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors (2023-12-05),

3. 11634409 - Compounds for the treatment of BRAF-associated diseases and disorders (2023-04-25),

4. 11414404 - Compounds for the treatment of BRAF-associated diseases and disorders (2022-08-16),

5. 11267812 - KRAS G12C inhibitors (2022-03-08),

6. 11028093 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2021-06-08),

7. 10730880 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors (2020-08-04),

8. 10669269 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2020-06-02),

9. 10633381 - KRas G12C inhibitors (2020-04-28),

10. 10189845 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2019-01-29),

11. 10125134 - KRas G12C inhibitors (2018-11-13),

12. 9809590 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2017-11-07),

13. 9670208 - Serine/threonine kinase inhibitors (2017-06-06),

14. 9174981 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2015-11-03),

15. 8987251 - Triazolopyridine compounds as PIM kinase inhibitors (2015-03-24),

Title: Erik James Hicken - Innovator in Pharmaceutical Research

Introduction

Erik James Hicken, based in Boulder, Colorado, is a prominent inventor in the pharmaceutical industry with an impressive portfolio of 18 patents. His contributions primarily focus on innovative compounds that target specific biological pathways, showcasing his commitment to advancing medical science.

Latest Patents

Hicken's latest patents include significant advancements in cancer treatment therapies. One notable patent is for compounds that inhibit KRas G12C. This invention is particularly pivotal as it focuses on compounds that irreversibly inhibit the activity of KRas G12C, alongside pharmaceutical compositions and methods for their applications. Another essential patent involves substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors. This innovation details compounds represented by a specified formula and their pharmaceutical salts, aimed at treating abnormal cell growth, including cancer, in affected subjects.

Career Highlights

Throughout his career, Erik Hicken has made substantial contributions while working with notable companies such as Array Biopharma Inc. and Mirati Therapeutics, Inc. These experiences have provided him with a strong foundation in pharmaceutical development and innovation, emphasizing his role in creating effective treatments for complex diseases.

Collaborations

Hicken has collaborated with esteemed professionals in the field, including John Joseph Gaudino and Mark Joseph Chicarelli. These partnerships highlight his ability to work within interdisciplinary teams, fostering a collaborative environment that drives forward-thinking solutions in pharmaceutical research.

Conclusion

Erik James Hicken stands out as a significant figure in the realm of pharmaceutical inventions, with a focus on innovative compounds that target cancer-related pathways. His extensive work, marked by multiple patents and collaborations, reflects his dedication to improving treatments for patients in need. As the pharmaceutical landscape evolves, innovators like Hicken continue to pave the way for new therapeutic options.

This text is generated by artificial intelligence and may not be accurate.